George Mason Research Foundation, Inc.

Stcube & Co., Inc.

Stsciences, Inc.

Ezra Myung Chul Chung

Stephen Sunghan Yoo

Yong-Soo Kim

Barney Bishop

Monique Van Hoek

Yong-Sik Bong

Andrew H Park

Provided herein are methods for treating cancer using molecules having an antigen binding fragment that immunospecifically binds to BTN1A1 or a BTN1A1 ligand, such as anti-BTN1A1 antibodies or anti-BTN1A1 ligand antibodies. Also provided herein are BTN1A1 ligands, such as Galectin-1, Galectin-9, Neuropilin-2, and B- and T-Lymphocyte Attenuator.

Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands

Provided herein are molecules, such as antibodies, that selectively bind to glycosylated BTLA (B- and T-lymphocyte attenuator) relative to unglycosylated BTLA. Methods for making and using such molecules are also provided, including methods for treating or diagnosing cancer. In some embodiments, the anti-glycosylated BTLA antibodies provided herein can immunospecifically bind to glycosylated wild-type BTLA (WT). In some embodiments, the anti-glycosylated BTLA antibodies provided herein can immunospecifically bind to one or more BTLA double mutants that retain only a single glycosylation site at BTLA N75, N94 or N110. In some embodiments, the anti-glycosylated BTLA antibodies provided herein show only background binding, if any, to a BTLA triple mutant, that retains none of BTLA's N75, N94, or N110 0-glycosylation sites.

Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)

Peptides having antimicrobial properties are described herein, as are compositions containing such peptides, and methods for using the peptides.

Antimicrobial peptides with wound healing activity

Growing community of inventors

North Potomac, MD, United States of America

Ezra Myung Chul Chung